把招募和招收不同人群作为优先事项——并取得成功

Maketherecruitmentandenrollmentof diverse populations a priority—and asuccess UseCase|Sitetrove Situation AsponsorisplanningforaPhaseIItrialofanovelIOagent in combination with chemotherapyin patientswithtriple negative breast cancerand needs to: IdentifyUSinvestigatorswhocouldsupporttheirstudy Understandthebreastcancerpatientlandscapeassociated with each investigator Enrichoperationalaspectstosupportgoalsandobjectivesoutlined in their FDA Race & Ethnicity Diversity Plan IdentificationofUSinvestigatorsandsiteswithexperience similar to your own protocol1 Sitetroveenablesyoutoselectthemostappropriateclinicaltrialinvestigatorsandsites,basedongeographicallocations,pastexperience,currentworkload,and patient accessibility. Build out your query includingthoseparametersthatarebestaligned with your needs. Herewehaveincluded: •TripleReceptorNegativeBreast Cancer•Phase I/II orII•MOAisImmuno-oncologytherapy•TrialTag/AttributeisIO/CytotoxicCombination•InvestigatorCountryisUnitedStates Wefound703USinvestigatorswhohaveworkedonanIOchemotherapycombination trial for TNBC. UseCase|Sitetrove Solution From here, you can further refineyourlistof703investigatorsusingSitetrove’sproprietaryInvestigatorPrioritization tool. Thetoolranksinvestigatorsinto3 tiers and incorporates aspects ofoverall trial experience, timing ofactivity,andthediseaseinwhichyouare searching. Investigators in tier 1 have thehighest probability to performwell,onaverageandasagroup,compared to investigators intiers 2 or 3. Limitingtotier1inourTNBCsearchprovidesuswith286USinvestigators. Didyouknow? Youcanalsoidentifytheinvestigatorswithlikelycapacityforyourtrial. By pressing the “export button” to create an Excel file containing the information ofthematchingtier1investigatorsandfilteringtheexport,youcanidentifyinvestigatorswho are *not currently tied* to a competitive trial and thus may have less competitionfor patients. Use Case| Sitetrove Solution Analysis of the patient landscape for US investigatorsto quickly understand:2 • which investigators have a high density of breast cancer patients• the demographic composition of these patients • First we can review the associated patient pools for the 286 tier 1 investigatorsmatching our search above. If you’d like to review patients associated with the full set of 703 US investigators, simply remove the tieringparameter to broaden your results.• Sort Investigator Patient Count in descending order to quickly identify investigatorswith the highest volume of breast cancer patients.• You can also filter by age, race/ethnicity, and gender demographics to identifyinvestigators best positioned to support diverse patient recruitment. Use Case| Sitetrove Solution Within the dashboards,you can also quicklyreview top-levelpatient insightsatthe following levels: • State• City• Investigator• Parent organization The dynamic heatmap enables you toview states with the greatest breast cancerpatient densityand understand the racial and ethnic composition of these patients. Use Case| Sitetrove Added Value The combination of Sitetrove’s robust investigator and site intelligence with comprehensivereal-world patient data allows you to: Quickly identify expert clinical investigatorswith relevant trial experience andaccess to diverse patient populations in one continuous workflow Tap into an additional layer of patient datato better inform feasibility andinvestigator and site selection activities Hit your diversity goals fasterby selecting investigators who are bestpositioned to recruit demographically diverse patients into your study early on Learn how you can leverage patient demographic dataalongside Sitetrove’s gold-standard clinical trial intelligence tooptimize investigator selection and hit your diversity goals faster. Citeline, aNorstellacompany, powers a full suite ofcomplementary business intelligence offerings to meet theevolvingneedsoflifescienceprofessionalstoacceleratetheconnectionoftreatmentstopatientsandpatientstotreatments.Thesepatient-focusedsolutionsandservicesdeliverandanalyzedata used to drive clinical, commercial and,regulatory-relateddecisions and create real-world opportunities for growth. Ourglobalteamsofanalysts,journalistsandconsultantskeeptheir fingers on the pulse of the pharmaceutical, biomedicalandmedtechindustries,coveringitallwithexpertinsights:keydiseases,clinicaltrials,drugR&Dandapprovals,marketforecasts,andmore.Formoreinformationononeoftheworld’smosttrustedlife science partners, visitCiteline.com